thebench.bio #1 Ecosystem for the Bio-Tech Industry

Regulatory Daily Summary

Regulatory Daily Summary: What Happened on October 5, 2026

FDA approves Jaypirca as first-line treatment for certain adults with CLL and SLL

A gene therapy also won approval. Drug tariffs are in effect, and manufacturing remediation has extended the FDA’s review of Novo Nordisk’s denecimig.

  • Updated
  • Read from 8 articles, 8 publications
  • B A +2

Today in brief

Jaypirca can now treat certain adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma who lack a 17p deletion.12 In the 282-patient Phase III trial, the drug improved progression-free survival versus bendamustine plus rituximab.1

The FDA approved a gene therapy for a rare lysosomal storage disorder, while U.S. tariffs of up to 100% on patented medicines and their ingredients took effect September 29.34 Companies face uncertainty over tariff exemptions and compliance, and Novo Nordisk said manufacturing-site remediation is extending the FDA’s review of denecimig.45

Jaypirca gains a first-line role in CLL and SLL

The FDA approved Lilly’s Jaypirca as an initial treatment for certain adults with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who lack a 17p deletion.12 The oral drug, pirtobrutinib, is a non-covalent Bruton tyrosine kinase (BTK) inhibitor taken at 200 milligrams daily.1

Approval was based on the Phase III BRUIN CLL-313 trial, which assigned 282 patients to Jaypirca or bendamustine plus rituximab.1 After a median 28 months, independent reviewers found a progression-free survival hazard ratio of 0.20.1 Median progression-free survival was not reached with Jaypirca and was 33.5 months with the comparator.1 Overall response rates were 94% with Jaypirca and 81% with the comparator regimen.1

Serious adverse reactions affected 28% of Jaypirca-treated patients, including pneumonia in 5%.1 Adverse events led to dose reductions in 3.6% of patients and treatment discontinuation in 4.3%.1

Tariffs take effect as companies seek clarity on exemptions

U.S. tariffs of up to 100% on patented medicines and their ingredients took effect September 29.4 Biotechnology companies say uncertainty over compliance, patent eligibility and product-by-product exemptions is disrupting routine work.4

Commerce guidance says reviews may weigh the disease, alternative treatments, U.S. patient numbers and availability abroad.4 Decisions will be case-specific, with no set deadline.4 Companies do not know whether they must pay tariffs before seeking refunds for products later granted exemptions.4

Industry experts warn that tariffs and compliance costs could divert resources from research, raise development costs and affect access to medicines.4 Smaller biotechnology firms may have less room to absorb those costs.4 Experts say firms that outsource manufacturing often cannot relocate production to the United States to seek tariff reductions.4 BIO research attributes 71% of industry output and 54% of new drug applications to small and midsize biotechnology companies.4

Manufacturing remediation extends FDA review of denecimig

Novo Nordisk said the FDA is continuing its review of denecimig, delayed by manufacturing-site remediation rather than clinical-data concerns.5

Novo continues to target a U.S. launch in the first half of 2027, subject to a regulatory decision.5 The company said the extended review will not change its 2026 financial outlook.5 Separately, the European medicines committee recommended authorizing denecimig, marketed as Frehemgo, for hemophilia A in adults and children.5

Also worth knowing

  • A

    The FDA is seeking public comment by November 20 on early ibogaine trial design, including dosing, safety monitoring, participant eligibility and oversight. Its proposed starting dose is no more than 10 mg/kg.6

  • B

    The FDA launched Operation TrialBlazer, a pilot for faster, risk-adjusted review before investigational new drug submissions. Applications are expected to open by the end of October.7

  • The FDA cleared Surrozen’s SZN-8141 for clinical testing in diabetic macular edema. The company intends to dose the first participant in its Phase Ib/IIa DUET trial in the fourth quarter of 2026.8

Also published